Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease and cancer : a systematic review and meta-analysis by Ma, Chenhan et al.
the bmj | BMJ 2017;359:j4849 | doi: 10.1136/bmj.j4849 1
RESEARCH
Effects of weight loss interventions for adults who are obese on 
mortality, cardiovascular disease, and cancer: systematic review 
and meta-analysis
Chenhan Ma,1 Alison Avenell,1 Mark Bolland,2 Jemma Hudson,1 Fiona Stewart,1  
Clare Robertson,1 Pawana Sharma,1 Cynthia Fraser,1 Graeme MacLennan3
ABSTRACT
OBJECTIVE
To assess whether weight loss interventions for adults 
with obesity affect all cause, cardiovascular, and 
cancer mortality, cardiovascular disease, cancer, and 
body weight.
DESIGN
Systematic review and meta-analysis of randomised 
controlled trials (RCTs) using random effects, 
estimating risk ratios, and mean differences. 
Heterogeneity investigated using Cochran’s Q and 
I2 statistics. Quality of evidence assessed by GRADE 
criteria.
DATA SOURCES
Medline, Embase, the Cochrane Central Register of 
Controlled Trials, and full texts in our trials’ registry 
for data not evident in databases. Authors were 
contacted for unpublished data.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
RCTs of dietary interventions targeting weight loss, 
with or without exercise advice or programmes, for 
adults with obesity and follow-up ≥1 year.
RESULTS
54 RCTs with 30 206 participants were identified. 
All but one trial evaluated low fat, weight reducing 
diets. For the primary outcome, high quality evidence 
showed that weight loss interventions decrease 
all cause mortality (34 trials, 685 events; risk ratio 
0.82, 95% confidence interval 0.71 to 0.95), with six 
fewer deaths per 1000 participants (95% confidence 
interval two to 10). For other primary outcomes 
moderate quality evidence showed an effect on 
cardiovascular mortality (eight trials, 134 events; risk 
ratio 0.93, 95% confidence interval 0.67 to 1.31), and 
very low quality evidence showed an effect on cancer 
mortality (eight trials, 34 events; risk ratio 0.58, 95% 
confidence interval 0.30 to 1.11). Twenty four trials 
(15 176 participants) reported high quality evidence 
on participants developing new cardiovascular events 
(1043 events; risk ratio 0.93, 95% confidence interval 
0.83 to 1.04). Nineteen trials (6330 participants) 
provided very low quality evidence on participants 
developing new cancers (103 events; risk ratio 0.92, 
95% confidence interval 0.63 to 1.36).
CONCLUSIONS
Weight reducing diets, usually low in fat and saturated 
fat, with or without exercise advice or programmes, 





Adults with obesity have an increased risk of 
premature mortality, cardiovascular disease, some 
cancers, type 2 diabetes, and many other diseases.1 2 
These associations inform the need for programmes 
to prevent obesity, but, apart from prevention of 
type 2 diabetes,3 4 limited evidence from randomised 
controlled trials (RCTs) shows that weight loss 
interventions can prevent serious harm for people 
with obesity. Evidence from cohort studies has led to 
debate that deliberate weight loss for people who are 
overweight or obese, with body mass index (BMI) ≤35 
kg/m2, might actually be harmful.5 Studies show that 
older people,6 and those with cardiovascular disease7 
who are less markedly obese, might experience adverse 
consequences from deliberate weight loss. Recent 
analyses by the Global BMI Mortality Collaboration, 
however, tried to limit confounding and corrected for 
reverse causality, finding that the risk of premature 
mortality was lowest at BMIs of 20-25.8
Association studies cannot tell us if deliberate 
weight loss in adults with obesity can reduce their 
risk of premature mortality, cardiovascular disease, or 
cancer. Only one systematic review and meta-analysis 
of RCTs of intentional weight loss in adults with obesity 
has examined this question.9 That review included 15 
trials, reporting a 15% relative reduction in premature 
mortality (risk ratio 0.85, 95% confidence interval 
0.73 to 1.00), but did not evaluate causes of death 
or cardiovascular and cancer outcomes.9 We knew of 
many other weight loss RCTs with mortality data, as 
well as cancer and cardiovascular outcomes, from our 
database of long term RCTs of weight loss interventions 
for adult obesity, which was developed for health 
technology assessments10 11 and is continually 
updated. We systematically reviewed long term (≥1 
year) RCTs of weight loss interventions for adults with 
obesity to examine the effects of any type of weight loss 
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WhAT IS AlReAdy knoWn on ThIS SuBjeCT
Whether recommendations to follow weight reducing diets can reduce premature 
mortality, cardiovascular disease, and cancer for adults who are obese is unclear
WhAT ThIS STudy AddS
Weight reducing diets, usually low in fat and saturated fat, with or without 
exercise advice or programmes, may reduce premature all cause mortality in 
adults who are obese
Our data provide supporting evidence for public health measures to prevent 
weight gain and facilitate weight loss using diets low in fat and saturated fat
RESEARCH
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diet on all cause, cardiovascular, and cancer mortality, 
cardiovascular disease, cancer, and body weight.
Methods
We adhered to the PRISMA (preferred reporting items 
for systematic reviews and meta-analyses) guidelines 
for systematic reviews of interventions.12 We used 
a prespecified protocol, registered with PROSPERO 
(CRD42016033217).13
Search strategy and selection criteria
We included RCTs with adults (mean or median age 
≥18 years) and a minimum follow-up of one year. 
Participants had a mean BMI ≥30 at baseline. Included 
trials had to be focused clearly on weight loss with 
a weight reducing diet, with or without advice for 
increasing physical activity and/or provision of a 
physical activity programme to attend, compared 
with a control intervention. We didn’t include trials in 
pregnant or postpartum women.
We sought summary data for three primary 
outcomes: all cause mortality, cardiovascular 
mortality, and cancer mortality. Secondary outcomes 
were participants with a new cardiovascular event, 
participants with a new cancer, and weight change. 
In our main analysis we used cardiovascular mortality 
and events as defined by the investigators but did 
not include the development of hypertension. We 
undertook post hoc analyses of cardiovascular 
mortality and cardiovascular events as defined in 
the American College of Cardiology/American Heart 
Association (ACC/AHA) guidelines.14
We identified RCTs by searching the full texts 
of trial reports in our database of all long term (≥1 
year) RCTs of weight loss interventions for adults 
with obesity used in our previous systematic reviews 
and health technology assessments. Our database is 
derived from previous search strategies compiled from 
Medline, Embase, and the Cochrane Central Register 
of Controlled Trials, from 1966 to December 2015.10 11 
We performed an updated search from August 2015 
to December 2016. We didn’t apply any language 
exclusions. In 2016-17 we contacted the authors of 48 
RCTs to clarify data or request unpublished outcome 
data, where trial reports implied that relevant data 
might be available; for example, when the trial 
reported hospital admissions or adverse events 
without giving further details.
Data analysis
AA and CM independently confirmed study eligibility. 
CM, FS, CR, and PS extracted data, which were then 
checked by a second author (AA, CM). Cancer outcome 
and cardiovascular outcome data (including coding 
outcomes defined by the ACC/AHA guideline14) were 
further adjudicated by MB, with differences resolved 
by Andrew Grey (associate professor in the Department 
of Medicine, University of Auckland). Two authors (AA, 
CM, FS, CR, PS) independently assessed quality using 
the Cochrane risk of bias tool.15 All differences were 
resolved by discussion.
We used random effects meta-analysis to analyse 
pooled outcome data. For binary outcomes, we 
estimated risk ratios and 95% confidence intervals, 
using all participants randomised for the denominators. 
We estimated weighted mean differences and 95% 
confidence intervals for continuous outcomes, 
giving preference to intention to treat data and data 
taking account of dropouts (preferentially baseline 
observation carried forward) if these were provided. 
We included outcome data from two cluster RCTs16 17 
using the correction method described in the 
Cochrane Handbook18 and the intraclass correlation 
coefficients reported in the original trial publications. 
We assessed heterogeneity between studies using 
Cochran’s Q statistic and the I2 test. We originally 
planned meta-regression to investigate heterogeneity 
in disease outcomes, but I2 tests for disease outcomes 
were 0%, so it was not appropriate. We carried out a 
sensitivity analysis with a random effects bayesian 
logistic regression model (with non-informative priors) 
using WinBUGS 1.4.319 because some trials reported 
few events, which may cause sparse data bias. We 
performed all other analyses using Stata Release 1420 
and used funnel plots to examine small study bias.
For all outcomes we performed prespecified 
subgroup analyses for sex, age (<60 v ≥60), BMI (<40 
v ≥40, later changed to <35 v ≥35 as we found no trial 
with BMI ≥40), glycaemic control (normal v impaired 
glucose tolerance or impaired fasting glucose v type 
2 diabetes), ethnicity (defined if ≥80% of participants 
belonged to an ethnic group, otherwise defined as 
mixed), physical activity interventions (none v advice 
only v exercise programme provided).
In post hoc additional analyses we added trials 
in any Asian population group if the mean BMI was 
≥25, as diseases associated with obesity are known 
to occur at lower BMI in Asian populations than other 
ethnic groups.21 No single BMI cut-off has been agreed 
to define obesity in Asian populations. Although the 
World Health Organization recommends 27.5 as a 
BMI threshold for a high risk of comorbidities,21 it 
also suggests that Asian countries develop their own 
specific BMI cut-offs for obesity. India and Japan have 
set ≥25 as the threshold for obesity,22 23 and in China 
the risk of comorbidities has been found to increase for 
BMI over 28.24
For all outcomes we performed two prespecified 
sensitivity analyses for allocation concealment (low 
risk of bias vs other risk of bias) and follow-up (<80% 
vs ≥80%).
We used GRADE (grading of recommendations, 
assessment, development, and evaluations) to judge 
the quality of the evidence for mortality, cardiovascular, 
and cancer outcomes.25
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing this report. CM and AA had full access to all 
study data and had final responsibility for the decision 
to submit for publication.
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Patient involvement
No patients or members of the public were involved in 
the development of research questions, the design of 
the study, or the development of outcome measures. 
No patients were asked to advise on interpretation or 
writing up of results. There are plans to disseminate 




We screened 1174 full text trial reports and 5982 
titles and abstracts (fig 1) and identified 54 RCTs for 
inclusion3 4 16 17 26-96 in the final review.
Table 1 provides details of the included studies, 
involving 30 206 adults with obesity. Nine trials 
(16.7%) included women only,2 6 44 45 50-52 77 88 94 
and two (3.7%) men only.58 72 Twelve trials (22.2%) 
recruited participants with no reported existing medical 
conditions or no reported increased risk of developing 
comorbidities related to obesity. Other trials recruited 
participants with increased risk of type 2 diabetes or 
hypertension or included participants that already had 
at least one of the following conditions: hypertension, 
type 2 diabetes, hyperlipidaemia, breast cancer, 
colorectal adenoma, psychiatric illnesses, cognitive 
impairment, osteoarthritis of the knee, coronary heart 
disease, or urinary incontinence.
Five trials (9.3%) were undertaken in Asian 
populations,16 17 59 75 80 but only one with BMI ≥30,2 16 
one trial (1.9%) was in a population of black people in 
the USA,50 31 (57.4%) in populations of white people, 
and 17 (31.5%) in mixed population groups. Thirty 
one (57.4%) trials took place in North America, 16 
(29.6%) in Europe, two (3.7%) in Australia, and one 
(1.9%) in Brazil. The four trials in Asian populations 
outside the UK had mean BMIs between 25 and 30. 
17 59 75 80 Thirty six (66.7%) trials had participants with 
a mean or median BMI <35, and 14 (25.9%) had BMIs 
≥35 (table 1).
Most trials recruited predominantly middle aged 
adults. Fourteen (25.9%) had a mean or median 
age at baseline of 60 years or more, none had a 
mean or median age of under 40 years. Thirty one 
(57.4%) trials followed participants for two years or 
longer, and seven (13.0%) trials (9,937 participants) 
followed participants for five years or longer. In 39 
trials (72.2%) the drop-out rate was <20% at trial 
completion.
Detailed descriptions of the weight loss diets were 
not always clearly provided in the trials. All but one of 
the trials described at least one of their interventions 
as being a low fat weight reduction diet (usually 
≤30% of energy as fat, although this was not always 
specified) or had sufficient information to establish 
that a reduction in fat intake was prescribed. Most 
trials also described the prescription of a reduction 
in saturated fat. One trial described using a 
balanced Mediterranean diet.79 One trial included 
the option to undertake a diet with ≤50 g/day of 
carbohydrate.96 Two weight loss trials specifically 
described diets to reduce low glycaemic index as 
part of their intervention,26  30 whereas other trials 
generally described diets that would be compatible 
with lowering glycaemic indices by increasing 
intake of complex carbohydrates and dietary fibre. 
Four trials (7.4%) were based on the DASH (dietary 
approaches to stop hypertension) diet.31 39 40 54 Eight 
(14.8%) trials based their diets on those of the US 
Diabetes Prevention Program,4 26 52 60 67 74 93 94 and 
four trials (7.4%) described basing their content in 
part on different editions of the Dietary Guidelines 
for Americans.64 69 72 76
Only three trials (5.6%) did not report providing 
exercise advice or an exercise programme.45 55 68 Twenty 
two trials (40.7%) provided an exercise programme for 
participants to attend, and 29 trials (53.7%) described 
providing advice to increase exercise only, without an 
exercise programme.
Supplementary figure 1 provides our risk of bias 
assessments for individual studies. Only 15 trials 
(27.8%) reported methods of randomisation and 
allocation concealment judged to be at low risk of 
bias. Blinding of participants and study personnel was 
rarely possible, but we judged that lack of blinding of 
outcome assessment would rarely have been a source 
of bias except for weight outcomes. Only 10 (18.5%) 
trials were judged to be at low risk for attrition bias, 
and 12 (22.2%) at low risk for reporting bias. Seven 
(13.0%) trials were judged to be at high risk of bias as 
a result of premature trial termination,52 65 75 change 
in the primary outcome,16 influence of a drug placebo 
in the control group,4 or trial investigators reporting 
that they were sponsored by grants from a commercial 
weight loss programme71 or that they were co-owners 
of a company developing products related to the 
research.72
Randomised controlled trial reports
identied in our obesity database (n=1174)
Abstracts identied in Medline, Embase, and
Cochrane Central Register of Controlled Trials
from August 2015 to December 2016 (n=5982)
Screened full text randomised
controlled trial reports (n=1174)
Screened abstracts (n=5982)
Reviewed in depth (n=176 abstracts + 89 randomised controlled trials)
Studies included in quantitative syntheses (n=54)
Excluded (n=211):
  Body mass index <30 (n=29)
  Body mass index <25 Asian (n=1)
  No suitable interventions (n=70)
  Unsuitable trial design (n=20)
  Unclear or unsuitable outcomes (n=10)
  Author said no outcomes (n=3) 
  No outcomes in paper (n=73)
  Duplicates (n=5)
Excluded randomised controlled trial
reports owing to: <12 month duration,
non-dietary interventions, no review
outcomes, or duplicates (n=1085)
Excluded abstracts owing to:
non-randomised controlled trial,
<12 month duration, BMI <30,
or duplicates (n=5806)
Fig 1 | Study selection
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Meta-analyses
Details of our adjudication processes for cardiovascular 
and cancer outcomes are provided in supplementary 
tables 1-3. Supplementary table 1 compares all 
cause mortality, cardiovascular mortality, and cancer 
mortality across all trials, showing that we were not 
always able to obtain causes of death from authors.
Based on the GRADE approach for judging quality 
of the evidence (supplementary table 4) we found high 
quality evidence from 34 trials (21 699 participants) 
providing data on all cause mortality (fig 2), which 
showed a decrease in premature mortality with weight 
loss interventions (n=34 trials, 685 events; risk ratio 
0.82, 95% confidence interval 0.71 to 0.95; I2=0%). 
The Look AHEAD trial had 54.6% of the weighting in 
the meta-analysis.65  66 Without this trial weight loss 
interventions were still associated with decreased all 
cause mortality (n=33 trials, 309 events; risk ratio 
0.78, 95% confidence interval 0.63 to 0.96; I2=0%). 
The funnel plot showed no evidence of small study 
bias (Egger’s test P=0.269, supplementary figure 2).
Fewer trials reported data for cardiovascular 
mortality and cancer mortality, resulting in 
considerable uncertainty in the estimates of effects 
of weight loss interventions on these outcomes. We 
found moderate quality evidence for an effect on 
cardiovascular mortality (n=8 trials, 134 events; risk 
ratio 0.93, 95% confidence interval 0.67 to 1.31; 
  Abbenhardt 2013
  Andrews 2011
  Aveyard 2016
  BeWEL 2014
  Bhopal 2014
  DPP 2002
  Daumit 2013
  Davis TAIM 1993
  Finnish DPS 2009
  Fitzgibbon 2010
  Gabriel 2011
  Goodwin 2014
  Greaves 2015
  Green 2015
  Heller 1988
  Horie 2016
  Hunt FFIT 2014
  Logue 2005
  Look AHEAD 2013
  Mengham 1999
  Oldroyd 2006
  Patrick 2011
  Penn 2009
  Perri 2014
  Rejeski CLIP 2011
  Rock 2015
  Shea ADAPT 2010
  Shea TONE 2011
  TOHP II 2007
  Toobert 2000
  Wing PRIDE 2010
  Yardley 2014
  de Vos 2014
  de Waard 1993
Overall: P=0.945, I2=0%
0.29 (0.01 to 7.07)
0.07 (0.00 to 1.64)
1.00 (0.32 to 3.10)
0.34 (0.01 to 8.27)
0.34 (0.01 to 8.16)
0.60 (0.14 to 2.51)
0.68 (0.12 to 4.01)
2.03 (0.38 to 11.02)
0.81 (0.42 to 1.57)
2.97 (0.12 to 72.15)
0.50 (0.05 to 5.52)
0.98 (0.06 to 15.49)
2.89 (0.12 to 69.47)
0.46 (0.04 to 5.01)
0.39 (0.02 to 9.32)
0.33 (0.01 to 7.95)
0.20 (0.01 to 4.15)
0.51 (0.05 to 5.60)
0.86 (0.71 to 1.05)
0.32 (0.01 to 7.73)
3.00 (0.13 to 71.46)
4.84 (0.23 to 100.33)
2.00 (0.19 to 21.37)
0.13 (0.01 to 3.12)
0.97 (0.09 to 10.56)
0.40 (0.08 to 2.05)
0.50 (0.28 to 0.89)
0.93 (0.65 to 1.33)
0.82 (0.44 to 1.51)
2.00 (0.09 to 45.12)
1.49 (0.06 to 36.37)
0.11 (0.00 to 2.58)
4.02 (0.45 to 35.65)
0.52 (0.18 to 1.53)
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Fig 2 | Random effects meta-analysis of the effects of weight loss interventions on all cause mortality. ADAPT=arthritis, 
diet, and activity promotion trial; CLIP=community level interventions for pre-eclampsia; DPP=diabetes prevention 
program; DPS=diabetes prevention study; FFIT=football fans in training; Look AHEAD=look action for health in 
diabetes; PRIDE=program to reduce incontinence by diet and exercise; TAIM=trial of antihypertensive interventions 
and management; TOHP=trials of hypertension prevention; TONE=trial of nonpharmacologic intervention in the 
elderly.
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I2=0%) and very low quality evidence for an effect on 
cancer mortality (n=8 trials, 34 events; risk ratio 0.58, 
95% confidence interval 0.30 to 1.11; I2=0%) (figs 3 
and 4). Limiting cardiovascular mortality to ACC/AHA 
defined events did not influence this result, as the data 
were identical (n=8 trials, 134 events; risk ratio 0.93, 
95% confidence interval 0.67 to 1.31; I2=0%).
Twenty four trials (15 176 participants) reported 
high quality evidence on participants developing 
new cardiovascular events (n=24, 1043 events; 
risk ratio 0.93, 95% confidence interval 0.83 to 
1.04; I2=0%). Using events classified according to 
ACC/AHA definitions, results were very similar (fig 
5, supplementary figure 3). Nineteen trials (6330 
participants) provided very low quality evidence on 
participants developing new cancers (n=19, 103 
events; risk ratio 0.92, 95% confidence interval 0.63 
to 1.36; I2=0%) (fig 6). Bayesian meta-analyses for 
all of the above outcomes provided similar results 
(supplementary table 5).
Interventions had a beneficial effect on weight 
change after one year (n=44, mean difference −3.42 kg; 
95% confidence interval −4.09 to −2.75 kg; I2=92%), 
after two years (n=20, mean difference −2.51 kg; 
95% confidence interval −3.42 to −1.60 kg; I2=89%) 
and after three or more years (n=8, mean difference 
−2.56 kg; 95% confidence interval −3.50 to −1.62 kg; 
I2=87%) (supplementary figures 4 to 6). Heterogeneity 
for each of these meta-analyses was very high (I2=87% 
to 92%), reflecting the wide diversity of weight loss 
interventions and their effects on weight.
Sensitivity analyses 
Sensitivity analyses for allocation concealment (low 
risk of bias versus other risk of bias) and completion 
of follow-up (<80% v ≥80% of participants completed) 
did not show any statistically significant heterogeneity 
for mortality, cardiovascular outcomes, or cancer 
outcomes (supplementary table 6).
Weight change at final follow-up was lower in trials 
with low risk of bias for allocation concealment (n=17, 
mean difference −2.33 kg; 95% confidence interval −2.87 
to −1.79 kg) than for trials with high or unclear risk of 
bias for allocation concealment (n=31, mean difference 
−3.24 kg; 95% confidence interval −4.00 to −2.49 kg).
Weight change at final follow-up was lower in trials 
with completed follow-up of less than 80% (n=15, MD 
−2.09 kg; 95% CI: −2.80 to −1.37 kg) than for trials 
with follow-up of 80% or more (n=33, MD −3.13 kg; 
95% CI: −3.71 to −2.55 kg).
  DPP 2002
  Daumil 2013
  Finnish DPS 2009
  Green 2015
  Logue 2005
  Look AHEAD 2013
  Oldroyd 2006
  Toobert 2000
Overall: P=0.810, I2=0%
0.50 (0.09 to 2.73)
5.10 (0.25 to 105.39)
1.16 (0.36 to 3.77)
0.18 (0.01 to 3.80)
1.02 (0.06 to 16.26)
0.91 (0.63 to 1.33)
3.00 (0.13 to 71.46)
2.00 (0.09 to 45.12)
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Fig 3 | Random effects meta-analysis of the effects of weight loss interventions on cardiovascular mortality. 
DPP=diabetes prevention program; DPS=diabetes prevention study.
  Daumit 2013
  Finnish DPS 2009
  Gabriel 2011
  Mengham 1999
  Penn 2009
  Perri 2014
  de Vos 2014
  de Waard 1993
Overall: P=0.967, I2=0%
0.34 (0.01 to 8.28)
0.75 (0.29 to 2.00)
0.50 (0.05 to 5.52)
0.32 (0.01 to 7.73)
1.00 (0.06 to 15.56)
0.13 (0.01 to 3.12)
1.00 (0.06 to 15.96)
0.44 (0.11 to 1.73)
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Fig 4 | Random effects meta-analysis of the effects of weight loss interventions on cancer mortality. DPS=diabetes 
prevention study.
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  Abed 2013
  Ackermann 2015
  Appel PREMIER 2003
  Ard 2016
  Bennett 2012
  Burke 2008
  DPP 2002
  Daumit 2013
  Green 2015
  Hunt FFIT 2014
  Katula 2013
  Logue 2005
  Look AHEAD 2013
  Ma 2013
  Messier 2013
  O’Neil 2016
  Oldroyd 2006
  Rejeski CLIP 2011
  Rock 2015
  Ross 2012
  Toobert 2000
  Uusitupa 1993
  Villareal 2011
  Wadden 2011
Overall: P=0.829, I2=0%
0.63 (0.30 to 1.29)
0.49 (0.04 to 5.37)
0.17 (0.02 to 1.62)
0.66 (0.32 to 1.37)
0.34 (0.01 to 8.35)
0.96 (0.06 to 15.16)
1.19 (0.68 to 2.08)
0.77 (0.27 to 2.15)
0.23 (0.03 to 2.03)
0.33 (0.01 to 8.16)
1.99 (0.18 to 21.68)
1.02 (0.06 to 16.26)
0.97 (0.85 to 1.10)
1.53 (0.06 to 37.09)
1.49 (0.06 to 36.24)
1.02 (0.06 to 16.19)
5.00 (0.25 to 100.89)
0.97 (0.25 to 3.79)
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Fig 5 | Random effects meta-analysis of the effects of weight loss interventions on participants with a cardiovascular 
event. CLIP=community level interventions for pre-eclampsia; DPP=diabetes prevention program; FFIT=football fans 
in training.
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Fig 6 | Random effects meta-analysis of the effects of weight loss interventions on participants developing cancer. 
DPS=diabetes prevention study.
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Subgroup analyses
We undertook many subgroup analyses, including 
post hoc analyses with the addition of trials in Asian 
populations with BMI ≥25 (supplementary table 
6, supplementary figures 7-9). Tests for subgroup 
differences for mortality, cardiovascular outcomes, 
and cancer outcomes provided weak evidence that 
participants without type 2 diabetes might be at lower 
risk of a new cardiovascular event than participants 
with type 2 diabetes or those with impaired glucose 
tolerance or impaired fasting glycaemia. Similarly, we 
found weak evidence that groups of white participants 
may be at lower risk of a new cardiovascular event 
than black, mixed, or Asian population groups when 
following weight loss interventions.
Subgroup analyses for weight change at final follow-
up provided weak evidence that participants aged 60 
or over lost more weight than younger participants 
and that participants in trials in Asian populations lost 
less weight than those in trials with other population 
groups. Similarly, we found weak evidence of better 
long term weight loss with trials that provided a 
physical activity programme, compared with trials 
that gave only physical activity advice or did not report 
providing physical activity advice.
discussion
We found high quality evidence that weight reducing 
diets for adults with obesity, usually low in fat and low 
in saturated fat, were associated with a 18% relative 
reduction in premature mortality over a median trial 
duration of two years, corresponding to six fewer deaths 
per 1000 participants (95% confidence interval two to 
10). This evidence provides a further reason for weight 
reducing diets to be offered alongside their already 
proven benefits, such as type 2 diabetes prevention. 
We were unable to show effects on cardiovascular 
and cancer mortality, or participants developing 
cardiovascular events or new cancers, although fewer 
trials reported events for these outcomes, resulting in 
much uncertainty around their effect estimates.
We identified 34 trials reporting mortality data 
compared with 15 in the previous systematic review by 
Kritchevsky and colleagues,9 which included weight 
loss interventions irrespective of baseline BMI, and 
we made very considerable efforts to clarify data and 
retrieve unpublished data from 48 trialists. We used a 
comprehensive search strategy with full text searching 
of trials in our obesity database. The trials we included 
were not necessarily designed to collect data on 
mortality, cardiovascular, and cancer outcomes, 
although larger trials generally were.65 66 81-87 We 
might have failed to identify all trials with outcome 
data, if trialists did not present these outcomes or 
presented them as unspecified adverse events. This 
may have biased results, although we could not see 
obvious funnel plot asymmetry for all cause mortality. 
Trials generally excluded participants with a recent 
diagnosis of cancer, but this was not always clear, 
so some participants may have had a recurrence of 
cancer, rather than a new event. Many of the trials had 
quite intensive control group interventions, and the 
unblinded nature of the interventions could have led 
to more medical treatment in control groups, tending 
to reduce differences between groups.65 Using GRADE 
to assess the quality of the evidence aids interpretation 
of the limitations of the evidence. We undertook 
sensitivity and subgroup analyses, including post 
hoc analyses, which should be regarded with caution. 
Individual patient data meta-analyses are required for 
further exploration of these subgroup findings.
In systematic reviews of controlled cohort studies, 
bariatric surgery has been associated with significant 
reductions in mortality, cardiovascular events, 
myocardial infarction, stroke, and risk of cancer.97 98 
A systematic review and meta-analysis of population 
prospective cohort studies by Flegal and colleagues 
found that BMIs of 30 to <35 were not associated with 
higher mortality, compared with BMIs of 18.5 to <25.5 
By contrast, the Global BMI Mortality Collaboration 
found that obesity (BMI 30 to <35) was associated 
with higher mortality; the investigators reduced 
reverse causality by examining data in non-smokers 
and excluding the first five years of follow-up.8 Their 
findings were consistent for men and women, up to 89 
years, and in the four continents examined. Similar 
findings were seen for deaths due to coronary heart 
disease, stroke, cancer, and respiratory disease. Our 
findings for BMI from RCT evidence are consistent with 
data from the Global BMI Mortality Collaboration.8 
Epidemiological studies can demonstrate the risks 
of higher BMIs and, therefore, the necessity for 
preventing obesity, but epidemiological associations 
between changes in body weight and changes in 
disease and mortality are often limited by the lack of 
information on the intentionality of that weight loss. 
Furthermore, treatment effects found in RCTs might 
differ from those expected in epidemiological studies, 
whereby epidemiological studies might overestimate 
benefits.99
Evidence from systematic reviews indicates that 
physical activity as an adjunct to weight reducing diets 
might be more effective than diets alone, in terms of 
weight loss and improvements in blood lipids and 
blood pressure.100 We were unable to show differences 
for mortality, cardiovascular disease, and cancer 
between weight reducing diets alone, diets plus advice 
on exercise, and diets plus an exercise programme 
for people to attend, for which we had limited 
statistical power. The majority of RCTs of weight loss 
interventions for obesity in adults have used low 
fat, weight reducing diets. But a recent systematic 
review by Tobias and colleagues101 found that low 
carbohydrate weight reducing diets were more effective 
for weight loss than low fat, weight reducing diets, but 
found no difference between low fat, weight reducing 
diets (defined as <30% fat) and higher fat, weight 
reducing diets on weight loss. Recent US guidelines102 
have been criticised for the lack of evidence from 
RCTs to support guidance.103 Thus, we must consider 
whether the type of weight loss diet, particularly low 
fat, weight reducing diets, usually with <10% of energy 
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as saturated fat, affects important health outcomes 
beyond cardiovascular risk factors or weight.100 That 
all except one of the interventions included here used 
a low fat, weight reducing diet provides important 
evidence on all cause mortality for weight reduction 
with this type of diet. We do not have the evidence to 
establish whether other forms of weight reducing diets 
have this effect, and we cannot dissociate the effects of 
weight loss from the use of low fat diets in our results.
We encourage investigators studying weight 
reducing diets to adhere to CONSORT guidance 
on reporting harms by always reporting clinically 
important outcomes and adverse events, irrespective 
of whether they think these events are related to the 
interventions.104 Collecting and reporting major 
disease outcomes in weight reducing trials for obesity 
is important, particularly cardiovascular disease and 
cancer. We did not have sufficient data to examine 
whether other types of diet or physical activity 
influence outcomes or whether certain groups in the 
population are more or less likely to benefit.
In conclusion, weight reducing diets, usually low 
in fat and low in saturated fat, with or without an 
exercise component, may reduce premature all cause 
mortality in adults who are obese. By implication, our 
data support public health measures to prevent weight 
gain and facilitate weight loss using these types of diet.
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